Acadian Asset Management LLC Olema Pharmaceuticals, Inc. Transaction History

Acadian Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$10.95 - $16.62 $1.67 Million - $2.54 Million	-152,746 Reduced 59.68%	103,179 $1.17 Million
Q4 2023 Feb 13, 2024	SELL	$10.53 - $17.14 $2.5 Million - $4.06 Million	-236,956 Reduced 48.08%	255,925 $3.59 Million
Q3 2023 Nov 13, 2023	SELL	$8.19 - $12.98 $707,845 - $1.12 Million	-86,428 Reduced 14.92%	492,881 $6.09 Million
Q2 2023 Aug 07, 2023	BUY	$3.22 - $9.65 $10,976 - $32,896	3,409 Added 0.59%	579,309 $5.23 Million
Q4 2022 Feb 14, 2023	BUY	$2.27 - $3.76 $6,635 - $10,990	2,923 Added 0.51%	575,900 $1.41 Million
Q3 2022 Nov 14, 2022	BUY	$2.72 - $5.88 $290,525 - $628,048	106,811 Added 22.91%	572,977 $1.58 Million
Q2 2022 Aug 09, 2022	BUY	$2.04 - $4.61 $716,223 - $1.62 Million	351,090 Added 305.09%	466,166 $1.9 Million
Q1 2022 May 12, 2022	BUY	$3.89 - $9.43 $56,226 - $136,301	14,454 Added 14.36%	115,076 $489,000
Q4 2021 Feb 10, 2022	BUY	$8.75 - $30.71 $880,442 - $3.09 Million	100,622 New	100,622 $940,000

136

58.7M

141K

23.1K

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $247M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.